Single-cell Omics Market size was valued at USD 4.44 billion in 2024 and is set to exceed USD 59.52 billion by 2037, expanding at over 22.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of single-cell omics is evaluated at USD 5.22 billion. Advancement in the studies of RNA sequencing is a major driver for the growth of the single-cell omics market. Since RNA sequencing provides a comprehensive snapshot of gene expression profiles in cells. By studying gene expression patterns at the single-cell level, researchers can identify and characterize distinct cell populations and subtypes within a tissue or organism. This has opened up new avenues for single-cell omics development.
Besides this, the rising investment in cell sequencing is also expected to augment the single-cell omics market growth. The National Institutes of Health (NIH) recently granted Texas A&M University System a USD 1.19 million grant for a collaboration between multiple disciplines to explore the deep links between genomes, nutrition, and health. The investment in cell sequencing is driven by the growing demand for single-cell omics research. Moreover, higher investment enables the development of innovative approaches for disease diagnosis, and therapeutic development.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
22.1% |
|
Base Year Market Size (2024) |
USD 4.44 billion |
|
Forecast Year Market Size (2037) |
USD 59.52 billion |
|
Regional Scope |
|
Application (Immunology, Neurology, Oncology, Cell Biology)
In 2037, the oncology sector is estimated to account for 46% share of the global single-cell omics market. The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. As of 2022, over 770 of the over 1,200 active clinical studies for cell and gene therapies were in oncology. Single-cell omics enable the identification of specific gene expression patterns or genetic alterations associated with therapeutic response or resistance. By profiling individual cancer cells, researchers can identify biomarkers that predict the likelihood of response to gene therapy. Furthermore, rising investment in cancer treatment has driven the segment’s growth. By building state-of-the-art cancer treatment centers and ensuring proper testing, screening, and treatment of cancers impacted by the COVID-19 pandemic, the Australian Government is investing USD 614 million in services
End User (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals)
The research organization segment is projected to hold around 55% share of the global single-cell omics market in the year 2037. The segment will expand at a notable CAGR over the projected time period. Rising investment by private sectors to accelerate the research in the research facilities. For instance, Schmidt Futures allocated USD 550 million to the latest research facility aimed at growing single-cell proteomics technologies in March 2023. Increased investment in research facilities allows for the establishment of advanced infrastructure dedicated to single-cell omics research. This includes the procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms.
Our in-depth analysis of the global single-cell omics market includes the following segments:
|
Application |
|
|
Product |
|
|
End User |
|
North American Market Forecast
The North America single-cell omics market is projected to be the largest with a share of about 40% by the end of 2037. The growth of the market is credited to rising investment in advanced healthcare technologies. Approximately USD 31 billion was invested in healthcare technology enterprises in the United States in the first quarter of 2022, which represents 28% of total investments. Investments in healthcare technologies, such as genomics, molecular diagnostics, and bioinformatics, support the development of precision medicine approaches. The integration of single-cell omics with healthcare technologies enables more accurate disease characterization, and patient stratification, driving the demand for single-cell omics technologies in the region.
APAC Market Statistics
The Asia Pacific single-cell omics market is expected to be the second largest, with a share of over 27% by the end of 2037, rising at a CAGR of almost 18% over the anticipated period. The rise in the collaboration of companies will bring new opportunities for market growth. For instance, Mission Bio, an innovator in high-throughput single-cell DNA and multi-omics analysis, recently signed a collaboration contract with SequMed, a Chinese pioneer in single-cell omics technology invention and applications. The partnership will allow Mission Bio's technological platform to be combined the clinical assay development and data analysis capabilities of SequMed in order to jointly create advanced single-cell assays for cancer detection, medication counseling, and prognostic tracking in China.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?